Long-term prostacyclin reduces pulmonary vascular resistance in severe primary pulmonary hypertension

Clinical and Experimental Rheumatology

Volumn 16, Issue 3, 1998, Pages 253-254

  Barst, R J ^a  

^a New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; PROSTACYCLIN; VASODILATOR AGENT;

ARTICLE; CLINICAL TRIAL; DRUG EFFECT; EVIDENCE BASED MEDICINE; HUMAN; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; TIME; VASCULAR RESISTANCE;

ANTIHYPERTENSIVE AGENTS; EPOPROSTENOL; EVIDENCE-BASED MEDICINE; HUMANS; HYPERTENSION, PULMONARY; PROSPECTIVE STUDIES; TIME FACTORS; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 0032066882     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. RUBIN LJ: Primary pulmonary hypertension. N EnglJ Med 1997; 336: 111-7.
2. RICH S, KAUFMAN E, LEVY PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
3. MCLAUGHLIN Wetal: Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998; 338:273-7.
4. DARST RJ, RUBIN LJ, MCGOON MD, CALDWELL EJ, LONG WA, LEVY PS: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121: 409-15.
5. BARST RJ, RUBIN U, LONG WA, el al.: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.